Generic Drug Makers To Benefit From India Patent Disclosures
This article was originally published in PharmAsia News
MUMBAI - India's patent office has decided to make public details about all patented drugs available in the country in an order to increase transparency in its pharma market, as well as boost the country's generic drug makers
You may also be interested in...
India Maintains Status Quo On Compulsory Licensing Provisions; Indian, MNC Lobbies Welcome Moves To Keep Flexibility But Future Doubts Linger
MUMBAI - Lobby groups from both the Indian generics industry and multinational companies hailed a decision by the Indian government to maintain the status quo on legal provisions that determine the conditions needed to trigger a compulsory license for a drug. But both sides expressed apprehension on how the present set of norms will unfold, fearing that future investments or market opportunities may be at risk if wrong moves are made
MUMBAI - After soliciting views from stakeholders on a "discussion paper" to outline conditions in which a compulsory license could be invoked, India's Department of Industrial Policy and Promotion is now trying to figure out what to do
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).